Table 1:
Characteristics of the study cohort
| Systemic Therapy | TARE | p | |
|---|---|---|---|
| n | 1210 | 304 | |
| Age (mean (SD)) | 62.10 (8.66) | 63.98 (8.83) | 0.001 |
| Sex = Female (%) | 233 (19.3) | 59 (19.4) | 1.000 |
| Charlson-Deyo Comorbidity Score (%) | 0.030 | ||
| 0 | 620 (51.2) | 177 (58.2) | |
| 1 | 287 (23.7) | 66 (21.7) | |
| 2 | 88 (7.3) | 26 (8.6) | |
| 3 | 215 (17.8) | 35 (11.5) | |
| Facility_Type (%) | <0.001 | ||
| Community | 53 (4.4) | 5 (1.6) | |
| Comprehensive | 268 (22.1) | 39 (12.8) | |
| Academic/research | 742 (61.3) | 227 (74.7) | |
| Network | 147 (12.1) | 33 (10.9) | |
| Year (%) | <0.001 | ||
| 2015 | 226 (18.7) | 93 (30.6) | |
| 2014 | 246 (20.3) | 86 (28.3) | |
| 2013 | 231 (19.1) | 43 (14.1) | |
| 2012 | 195 (16.1) | 36 (11.8) | |
| 2011 | 192 (15.9) | 24 (7.9) | |
| 2010 | 120 (9.9) | 22 (7.2) | |
| Bilirubin | 1.89 (1.60) | 1.31 (1.09) | <0.001 |
| mean (SD) | |||
| Creatinine | 1.40 (1.15) | 1.25 (1.03) | 0.041 |
| mean (SD) | |||
| International Normalized Ratio | 1.37 (0.67) | 1.31 (0.66) | 0.118 |
| mean (SD) | |||
| Alpha-Fetoprotein (%) | 0.066 | ||
| <40 ng/mL | 307 (25.4) | 75 (24.7) | |
| 40 to 399 ng/mL | 242 (20.0) | 76 (25.0) | |
| 400 ng/mL or higher | 600 (49.6) | 131 (43.1) | |
| Unknown | 61 (5.0) | 22 (7.2) | |
| Tumor Extent (%) | 0.004 | ||
| Single lobe | 661 (54.6) | 194 (63.8) | |
| Multiple lobes | 470 (38.8) | 101 (33.2) | |
| Unspecified | 79 (6.5) | 9 (3.0) | |
| Maximum tumor size (%) | 0.098 | ||
| <50 mm | 281 (23.2) | 67 (22.0) | |
| 50 mm or greater | 731 (60.4) | 201 (66.1) | |
| Not determined | 198 (16.4) | 36 (11.8) |